Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Masitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT known ✓ | P10721 | 13/20 | 1.00 |
| ▸ | PDGFRA known ✓ | P16234 | 4/20 | 1.00 |
| ▸ | PDGFRB known ✓ | P09619 | 4/20 | 1.00 |
| ▸ | ABL1 | P00519 | 19/20 | 1.00 |
| ▸ | BCR | P11274 | 13/20 | 1.00 |
| ▸ | ABL2 | P42684 | 8/20 | 1.00 |
| ▸ | SRC | P12931 | 3/20 | 1.00 |
| ▸ | EGFR | P00533 | 2/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 2/20 | 1.00 |
| ▸ | LCK | P06239 | 2/20 | 1.00 |
| ▸ | FYN | P06241 | 2/20 | 1.00 |
| ▸ | CSF1R | P07333 | 2/20 | 1.00 |
| ▸ | LYN | P07948 | 2/20 | 1.00 |
| ▸ | FGR | P09769 | 2/20 | 1.00 |
| ▸ | BRAF | P15056 | 2/20 | 1.00 |
| ▸ | NQO2 | P16083 | 2/20 | 1.00 |
| ▸ | EPHA8 | P29322 | 2/20 | 1.00 |
| ▸ | FRK | P42685 | 2/20 | 1.00 |
| ▸ | BLK | P51451 | 2/20 | 1.00 |
| ▸ | DDR1 | Q08345 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Masitinib SCHEMBL29353195 | 1.00 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Masitinib SCHEMBL29355443 | 1.00 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Masitinib SCHEMBL2297143 | 0.97 | ABL1 (0.94) | ABL1BCRKITABL2PDGFRA | |
| Masitinib SCHEMBL1096348 | 0.97 | ABL1 (0.94) | ABL1BCRKITABL2PDGFRA | |
| Masitinib SCHEMBL30024483 | 0.97 | ABL1 (0.94) | ABL1BCRKITABL2PDGFRA | |
| SCHEMBL3301373 | 0.95 | ABL1 (0.91) | ABL1BCRKITABL2PDGFRA | |
| SCHEMBL16085058 | 0.94 | ABL1 (0.89) | ABL1BCRKITABL2PDGFRA | |
| SCHEMBL717173 | 0.94 | ABL1 (0.88) | ABL1BCRKITABL2PDGFRA | |
| SCHEMBL17177780 | 0.93 | ABL1 (0.88) | ABL1BCRKITABL2PDGFRA | |
| SCHEMBL26359118 | 0.93 | ABL1 (0.87) | ABL1BCRKITABL2PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 285 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3964206-A1 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2022-03-09 | — | — | EP | claimed |
| EP-2786765-B1 | Composition for combination therapy comprising an anti-C-met antibody and a FGFR inhibitor | SAMSUNG ELECTRONICS CO LTD (KR) | 2018-10-03 | — | — | EP | claimed |
| EP-2117531-B1 | COMBINATION TREATMENT OF SOLID CANCERS WITH ANTIMETABOLITES AND TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2016-11-02 | — | — | EP | claimed |
| US-8993573-B2 | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors | AB SCIENCE (FR) | 2015-03-31 | — | — | US | claimed |
| EP-2366703-B1 | Polymorph form of 2-amino (nitroaryl) thiazole derivative | AB SCIENCE (FR) | 2014-07-30 | — | — | EP | claimed |
| US-20140088108-A1 | 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITIORS | AB SCIENCE (FR) | 2014-03-27 | — | — | US | claimed |
| CN-101657446-B | Method for synthesizing 2-aminothiazole compounds as kinase inhibitors | AB SCIENCE | 2013-05-15 | — | — | CN | claimed |
| US-20120196871-A1 | PROCESS FOR THE SYNTHESIS OF 2-AMINOTHIAZOLE COMPOUNDS AS KINASE INHIBITORS | AB SCIENCE (FR) | 2012-08-02 | — | — | US | claimed |
| US-8227470-B2 | Combination treatment of solid cancers with antimetabolites and tyrosine kinase inhibitors | AB SCIENCE (FR) | 2012-07-24 | — | — | US | claimed |
| US-8153792-B2 | Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors | AB SCIENCE (FR) | 2012-04-10 | — | — | US | claimed |
| EP-2366703-A1 | Polymorph form of 2-amino (nitroaryl) thiazole derivative | AB Science (FR) | 2011-09-21 | — | — | EP | claimed |
| EP-2118099-B1 | PROCESS FOR THE SYNTHESIS OF 2-AMINOTHIAZOLE COMPOUNDS AS KINASE INHIBITORS | AB SCIENCE (FR) | 2011-07-06 | — | — | EP | claimed |
| US-20100121063-A1 | PROCESS FOR THE SYNTHESIS OF 2-AMINOTHIAZOLE COMPOUNDS AS KINASE INHIBITORS | AB SCIENCE (FR) | 2010-05-13 | — | — | US | claimed |
| US-20100093750-A1 | COMBINATION TREATMENT OF SOLID CANCERS WITH ANTIMETABOLITES AND TYROSINE KINASE INHIBITORS | AB SCIENCE | 2010-04-15 | — | — | US | claimed |
| EP-2118099-A2 | PROCESS FOR THE SYNTHESIS OF 2-AMINOTHIAZOLE COMPOUNDS AS KINASE INHIBITORS | AB Science (FR) | 2009-11-18 | — | — | EP | claimed |
| CN-100491374-C | 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as C-KIT inhibitors | AB SCIENCE (FR) | 2009-05-27 | — | — | CN | claimed |
| US-7423055-B2 | e.g., 2-(2-methyl-5-amino)phenyl-4-(3-pyridyl)-thiazole; c-kit inhibitors; treating cell proliferative, metabolic, allergic, and degenerative disorders. | AB SCIENCE (FR) | 2008-09-09 | — | — | US | claimed |
| US-20080207572-A1 | Use of Dual C-Kit/Fgfr3 Inhibitors for Treating Multiple Myeloma | AB SCIENCE | 2008-08-28 | — | — | US | claimed |
| WO-2008098949-A2 | PROCESS FOR THE SYNTHESIS OF 2-AMINOTHIAZOLE COMPOUNDS AS KINASE INHIBITORS | AB SCIENCE (FR) | 2008-08-21 | — | — | WO | claimed |
| EP-1525200-B1 | 2-(3-AMINOARYL)AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS | AB SCIENCE (FR) | 2007-10-10 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207572-A1 | Use of Dual C-Kit/Fgfr3 Inhibitors for Treating Multiple Myeloma | KIT, FGFR3, AURKC | KIT 1/4885PDGFRA 377/4885PDGFRB 481/4885 |
| US-20100121063-A1 | PROCESS FOR THE SYNTHESIS OF 2-AMINOTHIAZOLE COMPOUNDS AS KINASE INHIBITORS | ABL1, ABL2, KIT | KIT 3/4885PDGFRA 107/4885PDGFRB 132/4885 |
| US-20140088108-A1 | 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITIORS | KIT, CHUK, CKS1B | KIT 1/4885PDGFRA 42/4885PDGFRB 41/4885 |
| US-20120196871-A1 | PROCESS FOR THE SYNTHESIS OF 2-AMINOTHIAZOLE COMPOUNDS AS KINASE INHIBITORS | ABL1, ABL2, ALK | KIT 4/4885PDGFRA 141/4885PDGFRB 183/4885 |
| US-20100093750-A1 | COMBINATION TREATMENT OF SOLID CANCERS WITH ANTIMETABOLITES AND TYROSINE KINASE INHIBITORS | ERBB2, ERBB3, ERBB4 | KIT 2283/4885PDGFRA 909/4885PDGFRB 1158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.